Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets
August 23, 2022 10:54 ET
|
Antisense Therapeutics Limited
World first study utilizing Somalogic SomaScan® assay# to assess up to 7,000 plasma proteins in Long COVID-19 patients has elucidated novel blood markers as potential diagnostic and therapeutic...
Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets
August 22, 2022 07:40 ET
|
Antisense Therapeutics Limited
World first study utilizing Somalogic SomaScan® assay# to assess up to 7,000 plasma proteins in Long COVID-19 patients has elucidated novel blood markers as potential diagnostic and therapeutic...
New Muscle Disease Indication for ATL1102 – Limb Girdle Muscular Dystrophy R2
June 22, 2022 09:15 ET
|
Antisense Therapeutics Limited
LGMDR2, also referred to as dysferlinopathy, is a rare genetic muscle disease caused by mutations in the dysferlin gene (DYSF)Animal study conducted at MCRI in collaboration with Jain Foundation in...
Antisense Therapeutics to present poster at world’s largest NMD conference
March 09, 2022 15:01 ET
|
Antisense Therapeutics Limited
New York, NY, March 09, 2022 (GLOBE NEWSWIRE) -- Antisense Therapeutics Limited [ASX: ANP | US OTC: ATHJY | FSE: AWY] will deliver a virtual presentation on its antisense drug at the Muscular...